Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy
Kamel, M., El-Sharkawy, E., Mounir, S., Shaker, M. (2020). Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy. EKB Journal Management System, 31(3), 421-426. doi: 10.21608/mjmr.2022.220333
Magdy M. Kamel; Esmat El-Sharkawy; Samir M. Mounir; Martina. G Shaker. "Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy". EKB Journal Management System, 31, 3, 2020, 421-426. doi: 10.21608/mjmr.2022.220333
Kamel, M., El-Sharkawy, E., Mounir, S., Shaker, M. (2020). 'Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy', EKB Journal Management System, 31(3), pp. 421-426. doi: 10.21608/mjmr.2022.220333
Kamel, M., El-Sharkawy, E., Mounir, S., Shaker, M. Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy. EKB Journal Management System, 2020; 31(3): 421-426. doi: 10.21608/mjmr.2022.220333

Assessment of Serum urokinase Plasminogen Activator Receptor (SuPAR) Levels in Childhood Epilepsy

Minia Journal of Medical Research
Volume 31, Issue 3, July 2020, Page 421-426  XML PDF (563.91 K)
Document Type: Original Article
DOI: 10.21608/mjmr.2022.220333
View on SCiNiTO View on SCiNiTO
Authors
Magdy M. Kamel1; Esmat El-Sharkawy2; Samir M. Mounir1; Martina. G Shaker3
1Department of Pediatrics, Faculty of Medicine, Minia University, El-Minia, Egypt.
2Department of Clinical Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt
3Department of Pediatrics, Faculty of Medicine, Minia University, El-Minia, Egypt
Abstract
Background: Epilepsy is the most common serious neurological disorder worldwide. 
Epilepsy is a chronic brain disorder affecting 3.5–5/1000 children in developed countries with 
41–187/100,000 cases reported every year. It increases the incidence of complications and 
mortality. Generalized convulsive seizures (GCSs) are associated with high demands on the 
cardiovascular system, thereby facilitating cardiac complications. SuPAR is an emerging 
marker of cardiovascular disease burden. Objectives: Aim of the study: To assess suPAR 
levels in childhood epilepsy in pediatric department of neurology, El-Minia university 
children and maternity hospital. Methods: This was a case control study. Our children (6 to 
60 months), who were divided into 2 groups; 30 children known epileptic and 30 children 
who were not epileptic and had no history of previous seizures or any illness that may induce 
convulsions or simulate epilepsy, served as control group matched in age and sex. Blood 
samples were collected and analyzed for suPAR levels. The studied groups: were subjected 
to careful detailed history taking, complete clinical examination, electroencephalography 
(EEG) and laboratory investigations including: suPAR, complete blood count (CBC), Creactive protein (CRP) and renal function tests. Results: Plasma concentrations of suPAR 
were statistically insignificantly higher in epileptic children than the other group (P 0.300). 
There were statistically male predominance (56.7%) > female (43.3%) regarding the gender 
of the epileptic children. There was a weak negative not significant correlation between
suPAR and the age of the child (r -0.093, p 0.396) and also, HB and suPAR (r -0.120, p 
0.275). While there were weak positive not significant correlation between; TLC and SuPAR 
(r 0.152, p 0.164) and also, between platelet count and suPAR (r 0.073, p 0.504) . 
Conclusion: The higher level of SuPAR in small number of epileptic patients may be due to 
brain inflammation effect and /or early cardiac injury.

Keywords
biomarker; suPAR; epilepsy; seizures; cardiac stress
Statistics
Article View: 45
PDF Download: 107